| Liza J Lopez, MD | |
|
3815 Highland Ave, Radiology Department, Downers Grove, IL 60515-1500 | |
| (630) 275-5900 | |
| Not Available |
| Full Name | Liza J Lopez |
|---|---|
| Gender | Female |
| Speciality | Diagnostic Radiology |
| Experience | 33 Years |
| Location | 3815 Highland Ave, Downers Grove, Illinois |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134105877 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 036093950 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Advocate Good Samaritan Hospital | Downers grove, IL | Hospital |
| Advocate Illinois Masonic Medical Center | Chicago, IL | Hospital |
| Central Dupage Hospital | Winfield, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Integrated Imaging Consultants Llc | 2567784408 | 166 |
News Archive
Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) for the investigational oral Bruton's tyrosine kinase (BTK) inhibitor ibrutinib, for two B-cell malignancy indications: previously treated mantle cell lymphoma (MCL) and previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
XenoPort, Inc. announced today its financial results for the fourth quarter and year ended December 31, 2013. Revenues for the fourth quarter were $2.9 million, compared to $0.5 million for the same period in 2012. Net loss for the fourth quarter was $19.1 million compared to net income of $3.0 million that resulted from a non-cash gain from XenoPort's litigation settlement with Glaxo Group Limited in the fourth quarter of 2012. At December 31, 2013, XenoPort had cash and cash equivalents and short-term investments of $58.7 million.
Today, the U.S. Food and Drug Administration released the results of the first survey of per- and polyfluoroalkyl substances (PFAS) in nationally distributed processed foods, including several processed baby foods, collected from the agency's Total Diet Study (TDS), which monitors levels of nutrients and contaminants in foods consumed in the U.S.
The International Association for the Study of Lung Cancer commends the U.S. Food and Drug Administration's (FDA) decision to grant accelerated approval for osimertinib (Tagrisso), an oral medication for advanced non-small cell lung cancer (NSCLC) patients with a specific epidermal growth factor receptor (EGFR) mutation (T790M) and following progression after previous EGFR inhibitor therapies.
A group of three gene variants, commonly inherited together, may provide clues to more successful treatment of pediatric eosinophilic esophagitis (EoE), a chronic inflammation of the food pipe often confused with gastroesophageal reflux disease (GERD).
› Verified 7 days ago
| Entity Name | Integrated Imaging Consultants Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700285335 PECOS PAC ID: 2567784408 Enrollment ID: O20141204001441 |
News Archive
Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) for the investigational oral Bruton's tyrosine kinase (BTK) inhibitor ibrutinib, for two B-cell malignancy indications: previously treated mantle cell lymphoma (MCL) and previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
XenoPort, Inc. announced today its financial results for the fourth quarter and year ended December 31, 2013. Revenues for the fourth quarter were $2.9 million, compared to $0.5 million for the same period in 2012. Net loss for the fourth quarter was $19.1 million compared to net income of $3.0 million that resulted from a non-cash gain from XenoPort's litigation settlement with Glaxo Group Limited in the fourth quarter of 2012. At December 31, 2013, XenoPort had cash and cash equivalents and short-term investments of $58.7 million.
Today, the U.S. Food and Drug Administration released the results of the first survey of per- and polyfluoroalkyl substances (PFAS) in nationally distributed processed foods, including several processed baby foods, collected from the agency's Total Diet Study (TDS), which monitors levels of nutrients and contaminants in foods consumed in the U.S.
The International Association for the Study of Lung Cancer commends the U.S. Food and Drug Administration's (FDA) decision to grant accelerated approval for osimertinib (Tagrisso), an oral medication for advanced non-small cell lung cancer (NSCLC) patients with a specific epidermal growth factor receptor (EGFR) mutation (T790M) and following progression after previous EGFR inhibitor therapies.
A group of three gene variants, commonly inherited together, may provide clues to more successful treatment of pediatric eosinophilic esophagitis (EoE), a chronic inflammation of the food pipe often confused with gastroesophageal reflux disease (GERD).
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Liza J Lopez, MD 11450 Circle Dr, Burr Ridge, IL 60527-5122 Ph: (630) 662-0085 | Liza J Lopez, MD 3815 Highland Ave, Radiology Department, Downers Grove, IL 60515-1500 Ph: (630) 275-5900 |
News Archive
Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) for the investigational oral Bruton's tyrosine kinase (BTK) inhibitor ibrutinib, for two B-cell malignancy indications: previously treated mantle cell lymphoma (MCL) and previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
XenoPort, Inc. announced today its financial results for the fourth quarter and year ended December 31, 2013. Revenues for the fourth quarter were $2.9 million, compared to $0.5 million for the same period in 2012. Net loss for the fourth quarter was $19.1 million compared to net income of $3.0 million that resulted from a non-cash gain from XenoPort's litigation settlement with Glaxo Group Limited in the fourth quarter of 2012. At December 31, 2013, XenoPort had cash and cash equivalents and short-term investments of $58.7 million.
Today, the U.S. Food and Drug Administration released the results of the first survey of per- and polyfluoroalkyl substances (PFAS) in nationally distributed processed foods, including several processed baby foods, collected from the agency's Total Diet Study (TDS), which monitors levels of nutrients and contaminants in foods consumed in the U.S.
The International Association for the Study of Lung Cancer commends the U.S. Food and Drug Administration's (FDA) decision to grant accelerated approval for osimertinib (Tagrisso), an oral medication for advanced non-small cell lung cancer (NSCLC) patients with a specific epidermal growth factor receptor (EGFR) mutation (T790M) and following progression after previous EGFR inhibitor therapies.
A group of three gene variants, commonly inherited together, may provide clues to more successful treatment of pediatric eosinophilic esophagitis (EoE), a chronic inflammation of the food pipe often confused with gastroesophageal reflux disease (GERD).
› Verified 7 days ago
Dr. Jonathan Tresley, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 3815 Highland Ave Dept Of, Downers Grove, IL 60515 Phone: 630-581-6511 Fax: 630-645-6404 | |
Dr. Preeti K Parhar, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 3815 Highland Ave, Downers Grove, IL 60515 Phone: 630-275-2300 | |
Rajeev M. Bhorade, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 3815 Highland Ave, Radiology Department, Downers Grove, IL 60515 Phone: 630-275-5900 | |
Howard K. O'neil, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 3815 Highland Ave, Radiology Department, Downers Grove, IL 60515 Phone: 630-275-5900 | |
Kurt R. Schultz, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 3815 Highland Ave, Radiology Department, Downers Grove, IL 60515 Phone: 630-275-5900 | |
Geoffrey H. Chun, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 3815 Highland Ave, Radiology Department, Downers Grove, IL 60515 Phone: 630-275-5900 |